eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 15
Clinical research

Oxidative stress markers in patients with hereditary angioedema

Stefano R. Del Giacco, Davide Firinu, Paola Lucia Minciullo, Maria Pina Barca, Paolo Emilio Manconi, Gennaro Tartarisco, Mariateresa Cristani, Antonella Saija, Sebastiano Gangemi

Arch Med Sci 2019; 15, 1: 92–98
Online publish date: 2017/07/31
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Hereditary angioedema due to C1-INH deficiency (C1-INH-HAE) or with normal C1-INH is characterized by recurrent swellings due to uncontrolled production of vasoactive mediators, among which bradykinin (BK) is crucial. Through the binding and activation of the two human BK-receptors, kinins may have dual beneficial and deleterious effects in vascular and inflammation physiopathology by inducing oxidative stress. We aimed to assess the serum concentrations of advanced glycation end products (AGEs) and advanced oxidation protein products (AOPPs) in patients affected by HAE.

Material and methods
Blood samples were collected to measure the serum concentrations of AGEs and AOPPs by spectrofluorimetric and spectrophotometric methods in patients affected by C1-INH-HAE and FXII-HAE during the remission state.

We showed that the circulating levels of AOPPs observed on control group (0.94 (0.36) nmol/mg) were significantly lower than those observed on the C1-INH-HAE group (1.68 (0.47) nmol/mg; p = 0.002) and FXII-HAE (1.50 (0.27) nmol/mg; p = 0.001). Moreover, the circulating levels of AGEs were significantly higher in C1-INH-HAE group (211.58 (151.05) AU/g; p = 0.02) than the FXII group (141.48 (89.59) AU/g), thus demonstrating a state of heightened oxidative stress.

Our observations show additional underlying events involved in HAE and are of central importance for further investigations of differences in bradykinin receptors signaling among the two disease subgroups.


hereditary angioedema, C1-inhibitor, bradykinin, oxidative stress, kinin

Cicardi M, Aberer W, Banerji A. et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014; 69: 602-16.
Bork K, Wulff K, Witzke G, Hardt J. Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations. Allergy 2015; 70: 1004-12.
Firinu D, Barca MP, Serusi L, et al. Switch to icatibant in a patient affected by hereditary angioedema with high disease activity: a case report. Int J Immunopathol Pharmacol 2012; 25: 269-73.
Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998; 351: 1693-7.
Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol 2003; 3: 311-7.
de Maat S, Björkqvist J, Suffritti C, et al. Plasmin is a natural trigger for bradykinin production in hereditary angioedema with factor XII mutations. J Allergy Clin Immunol 2016; 138: 1414-23.e9.
Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006; 343: 1286-9.
Charignon D, Ghannam A, Defendi F, et al. Hereditary angioedema with F12 mutation: factors modifying the clinical phenotype. Allergy 2014; 69: 1659-65.
Holguin F, Fitzpatrick A. Obesity, asthma, and oxidative stress. J Appl Physiol (1985) 2010; 108: 754-9.
Kalousova M, Zima T, Tesar V, Dusilova-Sulkova S, Skrha J. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat Res 2005; 579: 37-46.
Piwowar A. [Advanced oxidation protein products. Part I. Mechanism of the formation, characteristics and property]. Pol Merkur Lekarski 2010; 28: 166-9.
Gangemi S, Allegra A, Aguennouz M, et al. Relationship between advanced oxidation protein products, advanced glycation end products, and S-nitrosylated proteins with biological risk and MDR-1 polymorphisms in patients affected by B-chronic lymphocytic leukemia. Cancer Investig 2012; 30: 20-6.
Gangemi S, Allegra A, Alonci A, et al. Increase of novel biomarkers for oxidative stress in patients with plasma cell disorders and in multiple myeloma patients with bone lesions. Inflamm Res 2012; 61: 1063-7.
Miraglia N, Assennato G, Clonfero E, Fustinoni S, Sannolo N. [Biologically effective dose biomarkers]. G Ital Med Lav Ergon 2004; 26: 298-301.
Musolino C, Allegra A, Saija A, et al. Changes in advanced oxidation protein products, advanced glycation end products, and s-nitrosylated proteins, in patients affected by polycythemia vera and essential thrombocythemia. Clin Biochem 2012; 45: 1439-43.
Kaplan AP, Joseph K, Silverberg M. Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol 2002; 109: 195-209.
Couture R, Blaes N, Girolami JP. Kinin receptors in vascular biology and pathology. Curr Vasc Pharmacol 2014; 12: 223-48.
Firinu D, Bafunno V, Vecchione G, et al. Characterization of patients with angioedema without wheals: the importance of F12 gene screening. Clin Immunol 2015; 157: 239-48.
Bafunno V, Bova M, Loffredo S, et al. Mutational spectrum of the c1 inhibitor gene in a cohort of Italian patients with hereditary angioedema: description of nine novel mutations. Ann Hum Genet 2014; 78: 73-82.
Firinu D, Colomba P, Manconi PE, et al. Identification of a novel and recurrent mutation in the SERPING1 gene in patients with hereditary angioedema. Clin Immunol 2013; 147: 129-32.
Gomez-Traseira C, Lopez-Lera A, Drouet C, et al. Hereditary angioedema caused by the p.Thr309Lys mutation in the F12 gene: a multifactorial disease. J Allergy Clin Immunol 2013; 132: 986-9.e1-5.
Bygum A, Fagerberg CR, Ponard D, Monnier N, Lunardi J, Drouet C. Mutational spectrum and phenotypes in Danish families with hereditary angioedema because of C1 inhibitor deficiency. Allergy 2011; 66: 76-84.
Di Lorenzo G, Minciullo PL, Leto-Barone MS, et al. Differences in the behavior of advanced glycation end products and advanced oxidation protein products in patients with allergic rhinitis. J Investig Allergol Clin Immunol 2013; 23: 101-6.
Bowler RP, Crapo JD. Oxidative stress in allergic respiratory diseases. J Allergy Clin Immunol 2002; 110: 349-56.
Spatari G, Saitta S, Cimino F, et al. Increased serum levels of advanced oxidation protein products and glycation end products in subjects exposed to low-dose benzene. Int J Hyg Environ Health 2012; 215: 389-92.
Faisant C, Armengol G, Bouillet , et al. Angioedema triggered by medication blocking the renin/angiotensin system: retrospective study using the French National Pharmacovigilance Database. J Clin Immunol 2016; 36: 95-102.
Patella V, Incorvaia C, Minciullo PL, et al. Oxidative stress markers in patients with hymenoptera venom allergy. Allergy Asthma Proc 2015; 36: 9-13.
Sala-Cunill A, Bjorkqvist J, Senter R, et al. Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions. J Allergy Clin Immunol 2015; 135: 1031-43e1036.
Gangemi S, Minciullo PL, Magliacane D, et al. Oxidative stress markers are increased in patients with mastocytosis. Allergy 2015; 70: 436-42.
Bossi F, Fischetti F, Regoli D, et al. Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol 2009; 124: 1303-10e1304.
Wu H, Roks AJ, Leijten FP, et al. Genetic variation and gender determine bradykinin type 1 receptor responses in human tissue: implications for the ACE-inhibitor-induced effects in patients with coronary artery disease. Clin Sci (Lond) 2014; 126: 441-9.
Chao J, Li HJ, Yao YY, et al. Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen-activated protein kinase activity. Hypertension 2007; 49: 490-7.
Kayashima Y, Smithies O, Kakoki M. The kallikrein-kinin system and oxidative stress. Curr Opin Nephrol Hypertens 2012; 21: 92-6.
Demirturk M, Gelincik A, Cinar S, et al. Increased eNOS levels in hereditary angioedema. Int Immunopharmacol 2014; 20: 264-8.
Demirturk M, Polat N, Guz G, et al. There is an increased risk of atherosclerosis in hereditary angioedema. Int Immunopharmacol 2012; 12: 212-6.
Czucz J, Schaffer G, Csuka D, et al. Endothelial cell function in patients with hereditary angioedema: elevated soluble E-selectin level during inter-attack periods. J Clin Immunol 2012; 32: 61-9.
Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005; 57: 27-77.
Kuhr F, Lowry J, Zhang Y, Brovkovych V, Skidgel RA. Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors. Neuropeptides 2010; 44: 145-54.
Tocchetti CG, Molinaro M, Angelone T, et al. Nitroso-redox balance and modulation of basal myocardial function: an update from the Italian Society of Cardiovascular Research (SIRC). Curr Drug Targets 2015; 16: 895-903.
Kuhlencordt PJ, Chen J, Han F, Astern J, Huang PL. Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation 2001; 103: 3099-104.
Talbot S, Lin JC, Lahjouji K, et al. Cigarette smoke-induced kinin B1 receptor promotes NADPH oxidase activity in cultured human alveolar epithelial cells. Peptides 2011; 32: 1447-56.
Dias JP, Talbot S, Senecal J, Carayon P, Couture R. Kinin B1 receptor enhances the oxidative stress in a rat model of insulin resistance: outcome in hypertension, allodynia and metabolic complications. PLoS One 2010; 5: e12622.
Dobo J, Major B, Kekesi KA, et al. Cleavage of kininogen and subsequent bradykinin release by the complement component: mannose-binding lectin-associated serine protease (MASP)-1. PLoS One 2011; 6: e20036.
Kaplan AP, Joseph K. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway. Adv Immunol 2014; 121: 41-89.
van Geffen M, Cugno M, Lap P, Loof A, Cicardi M, van Heerde W. Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency. Clin Exp Immunol 2012; 167: 472-8.
Reshef A, Zanichelli A, Longhurst H, Relan A, Hack CE. Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk. Allergy 2015; 70: 506-13.
Bjorkqvist J, de Maat S, Lewandrowski U, et al. Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. J Clin Invest 2015; 125: 3132-46.
Kajdacsi E, Jani PK, Csuka D, et al. Novel vasoregulatory aspects of hereditary angioedema: the role of arginine vasopressin, adrenomedullin and endothelin-1. J Clin Immunol 2016; 36: 160-70.
Bas M, Kirchhartz N, Hochfeld J, et al. Potential role of vasomotor effects of fibrinogen in bradykinin-induced angioedema. J Allergy Clin Immunol 2008; 121: 969-75e962.
Torbitz VD, Bochi GV, de Carvalho JA, de Almeida Vaucher R, da Silva JE, Moresco RN. In vitro oxidation of fibrinogen promotes functional alterations and formation of advanced oxidation protein products, an inflammation mediator. Inflammation 2015; 38: 1201-6.
Ahearn J, Shields KJ, Liu CC, Manzi S. Cardiovascular disease biomarkers across autoimmune diseases. Clin Immunol 2015; 161: 59-63.
Roy-O’Reilly M, McCullough LD. Sex differences in stroke: the contribution of coagulation. Exp Neurol 2014; 259: 16-27.
Xing D, Nozell S, Chen YF, Hage F, Oparil S. Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol 2009; 29: 289-95.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe